Cargando…

Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling

Plateable human hepatocytes with human plasma were utilized to generate the uptake transporter kinetic data for pravastatin, an organic anion‐transporting polypeptide (OATP) transporter substrate. The active hepatic uptake of pravastatin was determined with a J(max) value of 134.4 pmol/min/million c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Jialin, Doshi, Utkarsh, Wright, Matthew, Hop, Cornelis E. C. A., Li, Albert P., Chen, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915609/ https://www.ncbi.nlm.nih.gov/pubmed/29388346 http://dx.doi.org/10.1002/psp4.12283

Ejemplares similares

3012 Functional consequences of pravastatin isomerization on OATP1B1-mediated transport
por: Wagner, Jonathan, et al.
Publicado: (2019)

Vitamin D Deficiency Impacts Exposure and Response of Pravastatin in Male Rats by Altering Hepatic OATPs
por: Peng, Jinfu, et al.
Publicado: (2022)

PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3
por: Yoshikado, Takashi, et al.
Publicado: (2018)

Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs
por: Liang, Ruifeng, et al.
Publicado: (2022)

Development of a Human Physiologically Based Pharmacokinetic (PBPK) Toolkit for Environmental Pollutants
por: Ruiz, Patricia, et al.
Publicado: (2011)

Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys
por: Cheng, Yaofeng, et al.
Publicado: (2021)

Altered Bioavailability and Pharmacokinetics in Crohn’s Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs
por: Alrubia, Sarah, et al.
Publicado: (2022)

High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application
por: Polagani, Srinivasa Rao, et al.
Publicado: (2012)

Structure of human drug transporters OATP1B1 and OATP1B3
por: Ciută, Anca-Denise, et al.
Publicado: (2023)

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients
por: Wang, Zhiqi, et al.
Publicado: (2019)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Transcriptional Regulation of Liver-Type OATP1B3 (Lt-OATP1B3) and Cancer-Type OATP1B3 (Ct-OATP1B3) Studied in Hepatocyte-Derived and Colon Cancer-Derived Cell Lines
por: Haberkorn, Bastian, et al.
Publicado: (2023)

Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model
por: Zhu, LiQin, et al.
Publicado: (2015)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Interstrain Variability in Trichloroethylene Metabolism in the Mouse
por: Chiu, Weihsueh A., et al.
Publicado: (2014)

Formulation and Pharmacokinetic Evaluation of Microcapsules Containing Pravastatin Sodium Using Rats
por: Puttegowda, Venkatesh Dinnekere, et al.
Publicado: (2016)

Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
por: Nies, Anne T, et al.
Publicado: (2013)

Preference of Conjugated Bile Acids over Unconjugated Bile Acids as Substrates for OATP1B1 and OATP1B3
por: Suga, Takahiro, et al.
Publicado: (2017)

Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3
por: Schnegelberger, Regina D., et al.
Publicado: (2022)

Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B‐mediated rifampicin interaction studies
por: Yoshikado, Takashi, et al.
Publicado: (2022)

Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: Possible role of CYP3A4 inhibition by pravastatin
por: Lee, Chong-Ki, et al.
Publicado: (2012)

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene
por: Trdan Lušin, Tina, et al.
Publicado: (2012)

Differential effects of metformin‐mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: A randomized controlled trial
por: Metry, Melissa, et al.
Publicado: (2022)

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects
por: Asaumi, Ryuta, et al.
Publicado: (2018)

Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants
por: Anderson, Kacey, et al.
Publicado: (2021)

Characterization of Human Erythrocytes as Potential Carrier for Pravastatin: An In Vitro Study
por: Harisa, Gamal El-din I., et al.
Publicado: (2011)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats
por: Cuello, W. S., et al.
Publicado: (2012)

Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials
por: Utembe, Wells, et al.
Publicado: (2020)

Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
por: Shaik, Abdul Naveed, et al.
Publicado: (2019)

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients
por: Kovar, Lukas, et al.
Publicado: (2020)

Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
por: Neuvonen, Mikko, et al.
Publicado: (2021)

Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans
por: Mallick, Pankajini, et al.
Publicado: (2020)

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction
por: Gill, Jaidip, et al.
Publicado: (2022)

Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations
por: Li, R, et al.
Publicado: (2014)

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates
por: Kovar, Lukas, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat
por: Sánchez-Dengra, Bárbara, et al.
Publicado: (2021)

More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter‐Mediated Clearances
por: Emami Riedmaier, Ariane, et al.
Publicado: (2016)

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel
por: Schilling, Uta, et al.
Publicado: (2020)

Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)
por: Nebot, Noelia, et al.
Publicado: (2021)

PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human
por: Campbell, Jerry L., et al.
Publicado: (2016)

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d5hosrl0p5endhj1dcn03rrm8m